RecruitingNot Applicable

REGistry of Long-term AnTithrombotic TherApy-2

Russia2,000 participantsStarted 2015-01-15

Plain-language summary

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Documented atrial fibrillation with CHA2DS2VASC \> 1 Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

What they're measuring

composite of major cardiovascular events

Timeframe: unclusion up to 5 years

composite of any bleeding events

Timeframe: unclusion up to 5 years

Trial details

NCT IDNCT04347187

SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Ekaterina Kropacheva, PhD

+79166760695 katekrab@list.ru

View on ClinicalTrials.gov More Atrial Fibrillation trials